Next Article in Journal
The Interplay between Cannabinoid Receptors and Microglia in the Pathophysiology of Alzheimer’s Disease
Next Article in Special Issue
Guideline-Optimised Treatment in Heart Failure—Do Higher Doses Reduce Systemic Inflammation More Significantly?
Previous Article in Journal
Oligometastatic Prostate Cancer—The Middle Child Syndrome
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 12
Issue 23
10.3390/jcm12237200
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study

by
Victoria Dworok
1,*,
Valentin Hähnel
1,
Marwin Bannehr
1,
Vera Paar
2,
Christoph Edlinger
1,2,
Michael Lichtenauer
2,
Christian Butter
1 and
Anja Haase-Fielitz
1,3
1
Department of Cardiology, Heart Center Brandenburg Bernau & Faculty of Health Sciences (FGW) Brandenburg, Brandenburg Medical School (MHB) Theodor Fontane, Ladeburger Straße 17, 16321 Bernau bei Berlin, Germany
2
Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, 5020 Salzburg, Austria
3
Institute of Social Medicine and Health System Research, Otto von Guericke University Magdeburg, 39120 Magdeburg, Germany
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2023, 12(23), 7200; https://doi.org/10.3390/jcm12237200
Submission received: 4 October 2023 / Revised: 21 October 2023 / Accepted: 16 November 2023 / Published: 21 November 2023
(This article belongs to the Special Issue Cardiovascular Diseases: Biomarker-Guided Therapy and Clinical Management)
Browse Figures
Versions Notes

Abstract

Right heart failure is a major challenge in clinical practice. Soluble Suppression of Tumorigenicity-2 (sST2), a member of the interleukin-1-receptor family, may have clinical prognostic value. The aim of this study was to analyze whether sST2 correlates with signs of acute right heart decompensation. This prospective single-center study included 50 patients admitted for clinical signs of predominant right heart decompensation. Signs of reduced blood supply to other organs (e.g., renal function parameter, troponin T, NT-proBNP), diuretics, and signs of venous congestion (inferior vena cava (IVC) diameter) with fluid retention (weight gain, peripheral edema) resulting from reduced RV function were analyzed. The degree of peripheral edema was defined as none, mild (5–6 mm depressible, regression in 15–60 s) or severe (>7 mm depressible, regression in 2–3 min). sST2 levels were measured at the day of hospitalization. A total of 78.7% showed severe peripheral edema. The median concentration of sST2 was 35.2 ng/mL (25.–75. percentiles 17.2–46.7). sST2 is correlated with the peripheral edema degree (rSpearman = 0.427, p = 0.004) and the diameter of IVC (r = 0.786, p = 0.036), while NT-proBNP (r = 0.114, p = 0.456), troponin T (r = 0.123, p = 0.430), creatinine-based eGFR (r = −0.207, p = 0.195), or cystatin C-based eGFR (r = −0.032, p = 0.839) did not. sST2, but no other established marker, is correlated with peripheral and central fluid status in patients with decompensated right heart failure.
Keywords: Soluble Suppression of Tumorigenicity 2 (sST2); biomarker; NT-proBNP; decompensated heart failure Soluble Suppression of Tumorigenicity 2 (sST2); biomarker; NT-proBNP; decompensated heart failure

Share and Cite

MDPI and ACS Style

Dworok, V.; Hähnel, V.; Bannehr, M.; Paar, V.; Edlinger, C.; Lichtenauer, M.; Butter, C.; Haase-Fielitz, A. Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study. J. Clin. Med. 2023, 12, 7200. https://doi.org/10.3390/jcm12237200

AMA Style

Dworok V, Hähnel V, Bannehr M, Paar V, Edlinger C, Lichtenauer M, Butter C, Haase-Fielitz A. Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study. Journal of Clinical Medicine. 2023; 12(23):7200. https://doi.org/10.3390/jcm12237200

Chicago/Turabian Style

Dworok, Victoria, Valentin Hähnel, Marwin Bannehr, Vera Paar, Christoph Edlinger, Michael Lichtenauer, Christian Butter, and Anja Haase-Fielitz. 2023. "Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study" Journal of Clinical Medicine 12, no. 23: 7200. https://doi.org/10.3390/jcm12237200

APA Style

Dworok, V., Hähnel, V., Bannehr, M., Paar, V., Edlinger, C., Lichtenauer, M., Butter, C., & Haase-Fielitz, A. (2023). Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study. Journal of Clinical Medicine, 12(23), 7200. https://doi.org/10.3390/jcm12237200

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop